Completed PHASE4 INTERVENTIONAL 2-arm NCT05221892

Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo

Double Blind Evaluation of Gamma-aminobutyric Acid Tartarate 100 mg, Glutamic Acid 100 mg, Dibasic Calcium Phosphate 50 mg, Thiamine Nitrate 25 mg, Pyridoxine Chloride 10 mg and Cyanocobalamin 5 mcg Versus Ginger for Vertigo-kinetosis

Sponsor: Fundação Educacional Serra dos Órgãos

Conditions Vertigo

Interventions Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin Ginger

Updated 4 times since 2022 Last updated: May 15, 2023 Started: Nov 22, 2021 Primary completion: Mar 31, 2023 Completion: Mar 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05221892, this PHASE4 trial focuses on Vertigo and remains completed. Sponsored by Fundação Educacional Serra dos Órgãos, it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jun 2023 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Mar 2022 — Jun 2023 [monthly]

Recruiting PHASE4

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundação Educacional Serra dos Órgãos

Data source: Fundação Educacional Serra dos Órgãos

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Teresópolis, Brazil